PHAR
Pharming Group is a global biopharmaceutical company focused on the development and commercialization of innovative medicines to serve unserved rare disease patients. It operates internationally, highlighting a portfolio of products and ongoing research aimed at addressing niche medical needs in the rare disease space. The company emphasizes patient-centric therapies and investor-focused updates, with headquarters connected to its European roots as reflected in its branding. Pharming is dedicated to advancing treatments for underserved patient populations through clinical development and strategic partnerships.
No recent deals for this company.